BioMarin to pay $840m for GSK castoff
This article was originally published in Scrip
Executive Summary
BioMarin Pharmaceutical is to buy rare disease-focused Prosensa for $680m in cash and $160m in contingent milestones if Prosensa's Duchenne muscular dystrophy product – the GSK-reject drisapersen – is approved quickly in the US and Europe.